These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 39392600)
1. Identification of RNA-binding protein RBMS3 as a potential biomarker for immunotherapy in bladder cancer. Praygod TF; Li J; Li H; Tan W; Hu Z; Zhou L Cancer Biomark; 2024 Aug; ():. PubMed ID: 39392600 [TBL] [Abstract][Full Text] [Related]
2. The construction and validation of an RNA binding protein-related prognostic model for bladder cancer. Chen F; Wang Q; Zhou Y BMC Cancer; 2021 Mar; 21(1):244. PubMed ID: 33685397 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model. Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787 [TBL] [Abstract][Full Text] [Related]
4. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer. Wang Z; Tu L; Chen M; Tong S BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144 [TBL] [Abstract][Full Text] [Related]
5. Identification of the Six-RNA-Binding Protein Signature for Prognosis Prediction in Bladder Cancer. Wu Y; Liu Y; He A; Guan B; He S; Zhang C; Kang Z; Gong Y; Li X; Zhou L Front Genet; 2020; 11():992. PubMed ID: 32983230 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of the functions and prognostic significance of RNA-binding proteins in bladder urothelial carcinoma. Guo C; Shao T; Jiang X; Wei D; Wang Z; Li M; Bao G Am J Transl Res; 2020; 12(11):7160-7173. PubMed ID: 33312357 [TBL] [Abstract][Full Text] [Related]
7. Integrating single-cell RNA-seq to identify fibroblast-based molecular subtypes for predicting prognosis and therapeutic response in bladder cancer. Wang J; Tan Z; Huang Y; Li C; Zhan P; Wang H; Li H Aging (Albany NY); 2024 Jul; 16(14):11385-11408. PubMed ID: 39033778 [TBL] [Abstract][Full Text] [Related]
8. Construction of cancer- associated fibroblasts related risk signature based on single-cell RNA-seq and bulk RNA-seq data in bladder urothelial carcinoma. Liu Y; Jian J; Zhang Y; Wang L; Liu X; Chen Z Front Oncol; 2023; 13():1170893. PubMed ID: 37124542 [TBL] [Abstract][Full Text] [Related]
9. Integrating Bulk and Single-Cell RNA Sequencing Reveals Heterogeneity, Tumor Microenvironment, and Immunotherapeutic Efficacy Based on Sialylation-Related Genes in Bladder Cancer. Tan Z; Chen X; Zuo J; Fu S; Wang J; Wang H J Inflamm Res; 2023; 16():3399-3417. PubMed ID: 37600224 [TBL] [Abstract][Full Text] [Related]
10. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma. Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217 [TBL] [Abstract][Full Text] [Related]
11. The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma. Wan Z; Wang Y; Li C; Zheng D Open Life Sci; 2023; 18(1):20220682. PubMed ID: 37588995 [TBL] [Abstract][Full Text] [Related]
12. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma. Chen L; Lin J; Wen Y; Chen Y; Chen CB Front Oncol; 2023; 13():1291720. PubMed ID: 38023241 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of scRNA-seq and bulk RNA-seq reveal the characteristics of disulfidptosis and a prognostic signature in BLCA. Deng H; Cheng F; Cheng S Aging (Albany NY); 2024 Mar; 16(6):5751-5771. PubMed ID: 38507521 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of CXCL12 expression reveals the significance of inflammatory fibroblasts in bladder cancer carcinogenesis and progression. Du Y; Cao J; Jiang X; Cai X; Wang B; Wang Y; Wang X; Xue B Cancer Cell Int; 2021 Nov; 21(1):613. PubMed ID: 34801033 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analysis Identified ETV7 as a Potential Prognostic Biomarker in Bladder Cancer. Li H; Zhang Y; Zheng S Biomed Res Int; 2021; 2021():8530186. PubMed ID: 34926692 [TBL] [Abstract][Full Text] [Related]
16. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer. Tan Z; Fu S; Zuo J; Wang J; Wang H Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832 [TBL] [Abstract][Full Text] [Related]
17. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer. Pan G; Xie H; Xia Y Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551 [TBL] [Abstract][Full Text] [Related]
18. Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome. Li C; Wan Z; Deng Q; Li Z; Wang Y Arch Esp Urol; 2023 Oct; 76(8):605-621. PubMed ID: 37960960 [TBL] [Abstract][Full Text] [Related]
19. Tao Y; Li X; Zhang Y; He L; Lu Q; Wang Y; Pan L; Wang Z; Feng C; Xie Y; Lai Z; Li T; Tang Z; Wang Q; Wang X Front Genet; 2022; 13():1057302. PubMed ID: 36568387 [No Abstract] [Full Text] [Related]
20. Construction and verification of a novel hypoxia-related lncRNA signature related with survival outcomes and immune microenvironment of bladder urothelial carcinoma by weighted gene co-expression network analysis. Cai D; Zhou Z; Wei G; Wu P; Kong G Front Genet; 2022; 13():952369. PubMed ID: 36118856 [No Abstract] [Full Text] [Related] [Next] [New Search]